CAMBRIDGE, UK I November 11, 2024 I STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announces that it ...
NGGT has initiated Phase I/II clinical trials in the U.S. and China to evaluate the safety and efficacy of NGGT002 for the treatment of Phenylketonuria ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback